# An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

> **NCT00932893** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 347 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** PF-02341066
- **DRUG:** Pemetrexed
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00932893
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-03
- **Final completion:** 2016-01
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932893, "An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00932893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*